Response Genetics, Inc. Announces Presentation of Lung Cancer Study Results at 2012 American Society of Clinical Oncology Annual Meeting
Published: May 30, 2012
LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today four presentations to be held during the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 to June 5, 2012. Study results are based on the company’s proprietary technology and approach.